Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (GB:0REN)
LSE:0REN
RESEARCH TOOLSreports
Holding GB:0REN?
Track your performance easily
0REN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsExpectations for the EARLY-TAVR trial in asymptomatic aortic stenosis to be positive and drive modest acceleration in TAVR market growth.
Share BuybackA $1 billion share buyback program has been announced.
ValuationThe stock is viewed as attractively valued at current levels.
Bears Say
Financial PerformanceManagement confirmed that 2025 EPS will be 'markedly lower' than EW's most recent 2024 EPS guidance.
Growth And Market CompetitionThe near-term outlook is clouded by TAVR growth decelerating and price competition in Europe, reducing the likelihood of a quick rebound.
Operational ChallengesDocs cited challenges with staffing, lab capacity, anesthesiology access, and growing multiple treatment lines at once, echoing EW's 2Q call-out.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.09% Insiders
24.37% Mutual Funds
38.34% Other Institutional Investors
36.20% Public Companies and
Individual Investors
0REN FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Currently, no data Available
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 23, 2024 which is in 32 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 24, 2024. The company reported CHF0.593 earnings per share for the quarter, beating the consensus estimate of CHF0.588 by CHF0.005.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is CHF0.57.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,400,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.593 in its last earnings report, beating expectations of CHF0.588. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 764M.
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF66.19 (― Upside)
CHF66.19 (― Upside)
Blogger Sentiment
Bullish
GB:0REN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $87.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.88%
12-Months-Change
Fundamentals
Return on Equity
21.35%
Trailing 12-Months
Asset Growth
12.16%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
0REN Earnings Call
Q2 2024
0:00 / 0:00
---
0REN Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
0REN Stock 12 Month Forecast
Average Price Target
―Edwards Lifesciences
―
Boston Scientific
―
Medtronic
―
Integra Lifesciences
―
Stryker
―
Best Analysts Covering 0REN
1 Year
1 Year Success Rate
22/34 ratings generated profit
1 Year Average Return
+13.22%
reiterated a buy rating 9 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +13.22% per trade.
---